Quick Answer
Altimmune, Inc. reported Diluted EPS of $1.00 per share (loss) for fiscal year 2025.
Altimmune, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.00 | +25.4% |
| 2024 | -$1.34 | +19.3% |
| 2023 | -$1.66 | +8.3% |
| 2022 | -$1.81 | +23.0% |
| 2021 | -$2.35 | -23.0% |
| 2020 | -$1.91 | -164.7% |
| 2016 | $2.95 | +6000.0% |
| 2015 | -$0.05 | +70.6% |
| 2014 | -$0.17 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.21 | +34.4% | +22.2% |
| June 30, 2025 | -$0.27 | +22.9% | -3.8% |
| March 31, 2025 | -$0.26 | +23.5% | +18.8% |
| September 30, 2024 | -$0.32 | +17.9% | +8.6% |
| June 30, 2024 | -$0.35 | -9.4% | -2.9% |
| March 31, 2024 | -$0.34 | +15.0% | +12.8% |
| September 30, 2023 | -$0.39 | +18.7% | -21.9% |
| June 30, 2023 | -$0.32 | +23.8% | +20.0% |
- Altimmune, Inc. showed an increase of +25.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2014–2025 period, Altimmune, Inc.’s diluted eps has declined by 488.2% (from $0.17 per share (loss) to $1.00 per share (loss)).
- The most recent figure is from Altimmune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: